Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

Retrieved on: 
Monday, September 7, 2020
Biotechnology, FDA, Medical devices, Health, Pharmaceutical, Medical equipment, Drug paraphernalia, Syringe, Dr. Reddy's Laboratories, Pharmacology, Companies, Health

The Faslodex brand and generic market had U.S. sales of approximately $407 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Key Points: 
  • The Faslodex brand and generic market had U.S. sales of approximately $407 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

Retrieved on: 
Thursday, September 3, 2020
Biotechnology, FDA, Pharmaceutical, Health, Psychoactive drugs, Drugs, RTT, Euphoriants, Methylphenidate, Dr. Reddy's Laboratories, Ketamine, Heroin

The Concerta brand and generic market had U.S. sales of approximately $1.159 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Key Points: 
  • The Concerta brand and generic market had U.S. sales of approximately $1.159 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Methylphenidate Hydrochloride Extended-Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.
  • Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism.
  • Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior.

Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

Retrieved on: 
Thursday, August 27, 2020
Biotechnology, FDA, Pharmaceutical, Health, Drugs, Health care, Health, RTT, NIFTY 50, Chelating agents, Thiols, Dr. Reddy's Laboratories, Penicillamine, Generic drug

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).
  • The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.
  • Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits.

Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India

Retrieved on: 
Wednesday, August 19, 2020
Infectious diseases, General Health, Pharmaceutical, Health, Chemistry, Physical sciences, States and union territories of India, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Organofluorides, Pyrazines, Dr. Reddy's Laboratories, Drug Controller General of India, Reddy

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India.
  • AVIGAN (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease.
  • M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddys Laboratories, said, "We are pleased to bring this important innovator medicine to the patients in India.
  • We believe that AVIGAN would provide an effective treatment option to the COVID-19 impacted patients in India.

Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market

Retrieved on: 
Tuesday, August 11, 2020
Biotechnology, FDA, Pharmaceutical, Health, Drugs, Health, RTT, Fluoroquinolone antibiotics, Otologicals, Combination drugs, Ciprofloxacin/dexamethasone, Dr. Reddy's Laboratories, Generic drug, Otic, Ciprofloxacin, Ofloxacin

We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients, says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddys Laboratories.

Key Points: 
  • We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients, says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddys Laboratories.
  • At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form.
  • The Ciprodex brand had U.S. sales of approximately $453 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle.

Dr. Reddy's to release Q1 FY 21 results on July 29th, 2020

Retrieved on: 
Monday, July 20, 2020
Biotechnology, Pharmaceutical, Health, Life sciences, CNX Nifty, Industries, Articles, Dr. Reddy's Laboratories, Biotechnology, Biosimilar, Lupin Limited

The operator will provide instructions on asking questions before and during the call.

Key Points: 
  • The operator will provide instructions on asking questions before and during the call.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19

Retrieved on: 
Wednesday, July 1, 2020
General Health, Infectious diseases, Health, Pharmaceutical, Clinical trials, Infectious diseases, Medical specialties, Medicine, Ebola, Fujifilm, Favipiravir, Dr. Reddy's Laboratories, Influenza, Reddy, Antiviral drug, Dr. Reddy’s, FUJIFILM Corporation

Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddys and GRA.

Key Points: 
  • Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddys and GRA.
  • FUJIFILM will provide Dr. Reddys and GRA with an array of data on Avigans preclinical and clinical studies that FUJIFILM has accumulated thus far.
  • Dr. Reddys and GRA will use this data for clinical studies targeting COVID-19 in regions where infection has been spreading.
  • Avigan Tablet, developed by FUJIFILM Toyama Chemical, was approved for manufacture and sale in Japan in 2014 as an influenza antiviral drug.

Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market

Retrieved on: 
Friday, June 19, 2020
General Health, Health, Science, Other Science, Pharmaceutical, Hormones, Drugs, Chemical compounds, Androstanes, Prostate cancer, Pyridines, 5α-Reductase inhibitors, Steroidal antiandrogens, Abiraterone acetate, Abiraterone, Johnson & Johnson, Dr. Reddy's Laboratories

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the U.S. Food and Drug Administration (USFDA).
  • The Zytiga brand and generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
  • Dr. Reddys Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.
  • Zytiga (abiraterone acetate) is a trademark of Johnson & Johnson corporation.

Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F

Retrieved on: 
Tuesday, June 16, 2020
General Health, Health, Science, Other Science, Pharmaceutical, SEC filings, States and union territories of India, India, Form 20-F, Dr. Reddy's Laboratories, Radar Doppler Multitarget, Reddy, New York Stock Exchange, U.S. Securities and Exchange Commission

Dr. Reddys Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2020 was filed with the United States Securities and Exchange Commission on June 15, 2020.

Key Points: 
  • Dr. Reddys Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2020 was filed with the United States Securities and Exchange Commission on June 15, 2020.
  • The Annual Report on Form 20-F is also available on Dr. Reddys website, www.drreddys.com and can be accessed by selecting SEC filings under Reports and Filings section under Investors.
  • ADS holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Companys registered office or by sending an e-mail to [email protected] .
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir

Retrieved on: 
Saturday, June 13, 2020
Infectious diseases, Pharmaceutical, Health, Health, CNX Nifty, Dr. Reddy's Laboratories, Pharmaceutical industry, Reddy, Food and Drug Administration, Remdesivir, Medication

Dr. Reddys will receive technology transfer from Gilead for manufacturing of this drug.

Key Points: 
  • Dr. Reddys will receive technology transfer from Gilead for manufacturing of this drug.
  • Dr. Reddys would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.
  • Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.